A biomarker test based on a combination of urine tissue inhibitor of metalloproteinases 2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7) was recently approved by the US Food and Drug Administration for AKI risk stratification. Here, IGFBP7 is linked to acute kidney injury.